^
Association details:
Biomarker:MET mutation
Cancer:Renal Cell Carcinoma
Drug Class:c-MET inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features

Published date:
08/07/2020
Excerpt:
Our data strongly suggest that MET represents a major oncogenic driver gene in BSA-PRCC, harboring a higher frequency of MET mutation that encourages to further explore the benefice of anti-MET targeted therapies for aggressive BSA-PRCC.
DOI:
10.1038/s41379-020-0645-6